VEGFA and neoplasm: The recent approval of bevacizumab by the USFDA as a first-line therapy for metastatic colorectal cancer confirmed that VEGF was a key mediator of tumor angiogenesis, and that blocking angiogenesis was an effective strategy to treat human cancers1.